论文部分内容阅读
目的 评估增强减影在骨骼肌肉恶性肿瘤MRI中的临床应用价值。方法 5 0例骨骼肌肉恶性肿瘤病人进行MR增强扫描 ,MR对比剂采用钆喷替酸葡甲胺 (Gd DTPA ,0 1mmol/kg) ,用T1W增强后的图像与增强前的图像进行减影。通过对比度 /噪声比值 (C/Ns值 )以及肿瘤影像征象清晰程度的比较 ,对MR减影与否进行评估。结果 MR对比增强减影图像比传统的T1W增强图像显示更清晰、更直观。所有病例都经手术和病理证实。 5 0例骨骼肌肉恶性肿瘤图像MR减影的C/Ns值比传统T1W增强图像的C/Ns值高。MR减影图像的C/Ns值为 10 9 74± 5 10 ( x±s) ,传统T1W增强图像的C/Ns值为 2 3 6 1± 3 16 (t=10 1 5 1,P <0 0 5 )。减影前后肿瘤影像征象的比较结果显示 :不规则边缘 (χ2 =7 86 ,P <0 0 5 )、肿瘤分叶 (χ2 =7 16 ,P <0 0 5 )和环形强化 (χ2 =7 4 4 ,P <0 0 5 ) ,对肿瘤影像征象清晰度差异的检出具有显著性意义。结论 MR对比增强减影比传统T1WI增强更能有效地显示骨骼肌肉恶性肿瘤。对比增强减影为检出和评估骨骼肌肉恶性肿瘤方面 ,提供了一个全新的诊断工具。
Objective To evaluate the clinical value of enhanced subtraction in MRI of skeletal muscular malignancies. Methods Fifty patients with skeletal muscular malignancies underwent MR contrast-enhanced MR imaging. MR contrast agents were treated with Gd DTPA (0 1 mmol / kg) and subtracted with T1W enhanced images before enhancement. MR subtraction was assessed by comparing the contrast / noise ratio (C / Ns) and the degree of tumor imaging sharpness. Results MR Contrast Enhancement Subtraction images are sharper and more intuitive than traditional T1W enhancement images. All cases were confirmed by surgery and pathology. The C / Ns values of MRI subtraction images of 50 skeletal muscle malignancies were higher than those of the conventional T1W enhancement images. The C / Ns value of MR subtraction images was 10 9 74 ± 5 10 (x ± s), and the C / Ns value of traditional T1W enhanced images was 2 3 6 1 ± 3 16 (t = 10 1 5 1, P <0 0 5). The comparison of tumor imaging before and after subtraction showed that there were no significant differences between the irregular edge (χ2 = 7 86, P <0 05), tumor lobulation (χ2 = 7 16, P 0 05) and annular enhancement 4, P <0 05), the detection of the difference of the sharpness of the tumor imaging sign has a significant meaning. Conclusions MR contrast enhancement subtraction is more effective than traditional T1WI enhancement in skeletal muscle malignancy. Contrast enhancement subtraction provides a whole new diagnostic tool for detecting and assessing skeletal muscle malignancies.